Cargando…
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
BACKGROUND: Recent evidence suggests that resistance to CD19 chimeric antigen receptor (CAR)-modified T cell therapy may be due to the presence of CD19 isoforms that lose binding to the single-chain variable fragment (scFv) in current use. As such, further investigation of CARs recognize different e...
Autores principales: | Gu, Runxia, Liu, Fang, Zou, Dehui, Xu, Yingxi, Lu, Yang, Liu, Bingcheng, Liu, Wei, Chen, Xiaojuan, Liu, Kaiqi, Guo, Ye, Gong, Xiaoyuan, Lv, Rui, Chen, Xia, Zhou, Chunlin, Zhong, Mengjun, Wang, Huijun, Wei, Hui, Mi, Yingchang, Qiu, Lugui, Lv, Lulu, Wang, Min, Wang, Ying, Zhu, Xiaofan, Wang, Jianxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487702/ https://www.ncbi.nlm.nih.gov/pubmed/32894185 http://dx.doi.org/10.1186/s13045-020-00953-8 |
Ejemplares similares
-
The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017) -
Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020) -
Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population
por: Wei, Hui, et al.
Publicado: (2018) -
Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023) -
Candidemia in Patients with Acute Leukemia: Analysis of 7 Years’ Experience at a Single Center in China
por: Gong, Xiaoyuan, et al.
Publicado: (2020)